A citation-based method for searching scientific literature

Dae-Seok Kim, Cristel V Camacho, W Lee Kraus. Exp Mol Med 2021
Times Cited: 17







List of co-cited articles
67 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
929
29

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
437
29

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
17

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
360
17

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
17

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Heng Zhu, Miaoyan Wei, Jin Xu, Jie Hua, Chen Liang, Qingcai Meng, Yiyin Zhang, Jiang Liu, Bo Zhang, Xianjun Yu,[...]. Mol Cancer 2020
50
17

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Charlie Gourley, Judith Balmaña, Jonathan A Ledermann, Violeta Serra, Rebecca Dent, Sibylle Loibl, Eric Pujade-Lauraine, Simon J Boulton. J Clin Oncol 2019
60
17

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
17

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
633
17

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
17

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
17

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
585
17


Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, Timothy A Yap. Cancer Discov 2017
267
17

How cells ensure correct repair of DNA double-strand breaks.
Joonyoung Her, Samuel F Bunting. J Biol Chem 2018
126
17

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.
Arnab Ray Chaudhuri, André Nussenzweig. Nat Rev Mol Cell Biol 2017
464
17

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
875
11

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, Bo Zhao, Nail Fatkhutdinov, Andrew V Kossenkov, Andrew J Wilson, Fiona Simpkins, David Speicher, Dineo Khabele,[...]. Cell Rep 2017
72
11


A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy, Jing Wang. Oncotarget 2018
47
11


Association of BRCA1 with Rad51 in mitotic and meiotic cells.
R Scully, J Chen, A Plug, Y Xiao, D Weaver, J Feunteun, T Ashley, D M Livingston. Cell 1997
11

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
752
11

Evaluating cell lines as tumour models by comparison of genomic profiles.
Silvia Domcke, Rileen Sinha, Douglas A Levine, Chris Sander, Nikolaus Schultz. Nat Commun 2013
761
11

Structural Basis of Homology-Directed DNA Repair Mediated by RAD52.
Mika Saotome, Kengo Saito, Takeshi Yasuda, Hideaki Ohtomo, Shusei Sugiyama, Yoshifumi Nishimura, Hitoshi Kurumizaka, Wataru Kagawa. iScience 2018
21
11

Structural basis for recruitment of BRCA2 by PALB2.
Antony W Oliver, Sally Swift, Christopher J Lord, Alan Ashworth, Laurence H Pearl. EMBO Rep 2009
117
11

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
405
11

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
11

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
11

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
644
11

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
658
11

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
11

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
Ahrum Min, Seock-Ah Im. Cancers (Basel) 2020
38
11

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Mary B Daly, Tuya Pal, Michael P Berry, Saundra S Buys, Patricia Dickson, Susan M Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L Hutton,[...]. J Natl Compr Canc Netw 2021
52
11

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
11


Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee,[...]. Nat Med 2018
337
11

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Saeed Rafii, Stan Kaye, Jasgit Sachdev, John Heymach, David C Smith,[...]. Cancer Discov 2017
214
11

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
11



Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Jacqueline Mersch, Michelle A Jackson, Minjeong Park, Denise Nebgen, Susan K Peterson, Claire Singletary, Banu K Arun, Jennifer K Litton. Cancer 2015
267
11

BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.
Weixing Zhao, Justin B Steinfeld, Fengshan Liang, Xiaoyong Chen, David G Maranon, Chu Jian Ma, Youngho Kwon, Timsi Rao, Weibin Wang, Chen Sheng,[...]. Nature 2017
136
11

Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Rohit Prakash, Yu Zhang, Weiran Feng, Maria Jasin. Cold Spring Harb Perspect Biol 2015
373
11

PARP inhibitors coming of age.
Shani Paluch-Shimon, Fatima Cardoso. Nat Rev Clin Oncol 2021
5
40

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
Samuel F Bunting, Elsa Callén, Nancy Wong, Hua-Tang Chen, Federica Polato, Amanda Gunn, Anne Bothmer, Niklas Feldhahn, Oscar Fernandez-Capetillo, Liu Cao,[...]. Cell 2010
11

DNA damage response.
Giuseppina Giglia-Mari, Angelika Zotter, Wim Vermeulen. Cold Spring Harb Perspect Biol 2011
189
11

Mechanism of eukaryotic homologous recombination.
Joseph San Filippo, Patrick Sung, Hannah Klein. Annu Rev Biochem 2008
11


PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Xuan Jiang, Xiaoying Li, Weihua Li, Huimin Bai, Zhenyu Zhang. J Cell Mol Med 2019
46
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.